Proteomics - Model Promarker - Diagnostic Tests Platform System

Proteomics International is applying its Promarker™ technology platform to create new diagnostic tests for chronic diseases with unmet medical need.

The Promarker™ platform uses mass spectrometry-based technology to identify the proteins that can be used as ‘a fingerprint’ of disease or other conditions.

Biomarker discovery, verification and analytical validation is available as a fee for service model, or through a collaborative partnership with Proteomics International. Read more.

The Promarker™ platform was used to discover, verify and analytically validate the panel of protein biomarkers for diabetic kidney disease. This technology platform continues to be used in the company’s certified laboratories as the commercialised test PromarkerD.

See our Promarker™ Pipeline for the areas of unmet need currently being investigated by Proteomics International.

Proteomics International’s Promarker™ Platform for protein biomarker discovery is a multi-step process. Grey lines indicate project progress as reported in The Company’s 2021 Annual Report.

Biomarker discovery, verification and analytical validation is available as a fee for service model, or through a collaborative partnership with Proteomics International. Read more.

The Promarker™ Platform is currently being used to investigate the protein ‘fingerprints’  associated with the following diseases of unmet need:

Diabetic Kidney Disease

Status update: Commercialised

Three biomarkers for Diabetic Kidney Disease identified by the Promarker™ Platform have been verified, validated, and developed into a commercially available test: PromarkerD.

Endometriosis

Status update: Clinical Validation study completed; Statistical analysis ongoing.

Endometriosis is a common and painful disease that affects one in nine women and girls [see Annual Report 2021: Window on the Science]. It occurs when tissue similar to the lining of the uterus grows into other parts of the body where it does not belong. At the moment, there is no simple way to test for the condition, which often causes pain and infertility, and costs Australia $9.7 billion each year.

The current gold standard for detection is an invasive laparoscopy, a surgical procedure where a camera is inserted into the pelvis through a small cut in the abdominal wall. On average, it takes women 7.5 years to be diagnosed. In August 2021, the Company signed a research agreement with the University of Melbourne and the Royal Women’s Hospital to collaborate on a non-invasive test for endometriosis. Proteomics International conducted a clinical validation study of its biomarkers on samples from the University of Melbourne and the Royal Women’s Hospital. Subsequent to the year end, the Company announced that an early version of its potential world-first blood test for endometriosis had successfully detected up to 78 per cent of people with the painful condition. The results were presented at the Fertility Society of Australia and New Zealand Annual Conference (FSANZ 2022). The Company will now seek to confirm the clinical performance of the new test in an independent patient cohort. To support this independent validation, Proteomics International announced an additional collaboration with St John of God Health Care.